Inactive Instrument

CMIC HLDG

Equities

2309

JP3359000001

CMIC : Overview of Financial Results For the 1st Quarter FY2022

January 31, 2022 at 01:42 am

Overview of Financial Results for FY2022 1st Quarter

CMIC HOLDINGS Co., Ltd.

January 31, 2022

Business segments and group companies

- Blue indicates overseas group companies.

	Segment	Products and services	CMIC Group companies (as of end of December 2021)

Pharmaceutical solutions

	CRO Business	Comprehensive support for research and development of	CMIC HOLDINGS Co., Ltd.
		disease prevention and treatment	CMIC Co., Ltd.
			CMIC ShiftZero K.K.
			CMIC Korea Co., Ltd.
			CMIC ASIA-PACIFIC, PTE. LTD.
			CMIC ASIA PACIFIC (MALAYSIA) SDN. BHD.
			CMIC Asia-Pacific (Hong Kong) Limited
			CMIC ASIA-PACIFIC (PHILIPPINES), INC.
			CMIC ASIA-PACIFIC (AUSTRALIA)PTY LTD
			CMIC ASIA-PACIFIC (THAI LAND) LIMITED
			CMIC ASIA-PACIFIC (VIETNAM) LIMITED
			CMIC (Beijing) Co., Ltd.
			CMIC DATA SCIENCE VIETNAM COMPANY LIMITED
			CMIC Pharma Science Co., Ltd.
			CMIC, INC.
	CDMO Business	Development and manufacturing support for pharmaceutical	CMIC CMO Co., Ltd.
		products and biopharmaceutical API from clinical to	CMIC CMO Korea Co., Ltd.
		commercial	CMIC CMO USA Corporation
			CMIC Bio Co., Ltd.
	Market Solutions Business	Medical, sales and marketing support for pharmaceuticals, and	CMIC Ashfield Co., Ltd.
		orphan drugs development to commercialization	OrphanPacific, Inc.
Healthcare solutions
	Site support Solutions Business	Comprehensive support of medical institutes and medical staff	CMIC HealthCare Institute Co., Ltd.
	Healthcare Revolution Business	Support individuals, local governments, etc. with solutions	CMIC HOLDINGS Co., Ltd.
		using a new ecosystem of health care	CMIC Solutions Co., Ltd.
			harmo Co., Ltd.	2
		CONFIDENTIAL	CMIC Well Co., Ltd.

Focus Activities of Mid-term Management Plan (FY2022-25)

Evolution of healthcare business

Comprehensive support for disease prevention, treatment R&D, and marketing

Contribution to sustainable society through services with high social benefits

Progress of 1st quarter of FY2022

Evolution of healthcare business

Support for COVID vaccination and PCR testing by local governments
- Utilization of the COVID-19 vaccination information management system "harmo® vaccine care with corona"
- Call center (to consult about adverse reactions), human resources support （Physician and nurse reference, admin staff)
Collaborating with Dai Nippon Printing (DNP) to Correct Vaccination Records and Support Data Utilization

• Vaccination records with improved accuracy by correcting entry errors in vaccination records are reflected using "harmo" for vaccination record presentation services, etc. to prevent erroneous vaccination

Progress of 1st quarter of FY2022

Comprehensive support for disease prevention, treatment R&D, and marketing

Accelerating & streamlining drug and device development
- Partnership with Science 37® to accelerate Decentralized Clinical Trials (DCTs) and speed up drug development
In the bioanalysis business, CMIC supports drug discovery in cutting-edge areas where modalities are diversifying, such as next-generation biopharmaceuticals and gene therapy drugs

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

CMIC Holdings Co. Ltd. published this content on 31 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 January 2022 06:41:04 UTC.

Latest news about CMIC HLDG

CMIC Holdings Delisted from Tokyo Stock Exchange	03-27	MT
CMIC to Delist After Shareholder Go-Ahead for Proposed Share Consolidation	03-04	MT
CMIC Holdings to Hold Shareholders Meeting to Vote on Share Consolidation and Amendment on March 4	02-01	MT
Japan's small cohort of listed firms led by women	01-31	RE
CMIC HOLDINGS Co., Ltd.(TSE:2309) dropped from S&P Global BMI Index	01-17	CI
CMIC Holdings Finalizes Tender Offer; Delisting Underway as Sole Shareholders Change	01-05	MT
SORA Corporation completed the acquisition of 55.42% CMIC HOLDINGS Co., Ltd..	01-03	CI
CMIC to Distribute 45 yen per Share Surplus Dividend, Plans to Buy Back Shares	11-16	MT
CMIC HOLDINGS Co., Ltd. Announces Dividend for the Year Ended September 30, 2023, Payable on December 1,2023	11-15	CI
Cmic Holdings Co., Ltd. Announces Retirement of Takeshi Hamaura as Corporate Director	11-07	CI
SORA Corporation made an offer to acquire 67.23% stake in CMIC HOLDINGS Co., Ltd. for ¥33.7 billion.	11-06	CI
CMIC HOLDINGS Co., Ltd. completed the acquisition of Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.	23-10-30	CI
CMIC Holdings Expands PHVC Business Model with Acquisition of Hamamatsu Pharma Research	23-10-27	MT
CMIC HOLDINGS Co., Ltd. signed a contract to acquire Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.	23-10-25	CI
CMIC Holdings Repurchases 114,000 Shares; Completes Share Buyback Mandate Approved in November 2022	23-08-14	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	23-08-14	CI
CMIC HOLDINGS Co., Ltd.'s Equity Buyback announced on November 8, 2022, has closed with 652,300 shares, representing 3.77% for ¥1,199.89 million.	23-08-09	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q3 2023 Earnings Call, Aug 01, 2023	23-07-31
CMIC Repurchases Shares in June	23-07-04	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	23-07-03	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q2 2023 Earnings Call, May 16, 2023	23-05-15
CMIC HOLDINGS Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	23-04-28	CI
CMIC HOLDINGS Co., Ltd. Announces Dividend for Second Quarter Ended March 31, 2023; Provides Year-End Dividend Guidance for the Fiscal Year Ending September 30, 2023	23-04-28	CI
CMIC HOLDINGS Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended September 30, 2023	23-04-28	CI
CMIC Repurchases Shares for 98 Million Yen in March	23-04-04	MT

Chart CMIC HLDG

Duration

Period

More charts

Company Profile

CMIC HOLDINGS Co., Ltd. mainly provides pharmaceutical development support services. The Contract Research Organization (CRO) segment offers monitoring, data management, pharmaceutical consulting and nonclinical services. The Contract Manufacturing Organization (CMO) segment is engaged in the entrusted manufacture of drugs for pharmaceutical companies. The Contract Sales Organization (CSO) segment is engaged in the operation and marketing support for medicinal products. The Health Care segment conducts site support institute (SMO) business, and provides health care information services. The Intellectual Property Development (IPD) segment develops and sells diagnostic products and orphan drugs.

Sector

More about the company